Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells

Xiaolong Huang¹†, Jingsong Huang²†, Dewen Leng³†, Shuo Yang¹†, Qi Yao⁴†, Jin Sun⁵ and Jun Hu⁶

Abstract

Background: Lung cancer stem cells (CSCs) are considered to be the seed of lung cancer, and CD133 is a marker of lung CSCs. Here, we developed gefitinib-loaded poly(ethylene glycol) 2000-distearoylphosphatidylethanolamine nanomicelles with CD133 aptamers (M-Gef-CD133) to eliminate CD133⁺ lung CSCs.

Methods: M-Gef-CD133 was prepared using a lipid-film-based approach. The targeting and activity of M-Gef-CD133 towards lung CSCs were evaluated.

Results: M-Gef-CD133 were small (25 nm) and showed enhanced cytotoxic effect towards CD133⁺ lung CSCs compared with non-targeted M-Gef and gefitinib. Notably, M-Gef-CD133 could significantly reduce tumor sphere formation and the percentage of CD133⁺ lung CSCs, indicating that it possesses selective toxicity against CD133⁺ lung CSCs.

Conclusions: The interaction of CD133 aptamers and CD133 shows promise in the delivery of gefitinib to CD133⁺ lung CSCs, and M-Gef-CD133 represents a promising treatment to target lung CSCs.

Keywords: Nanomicelles, Lung cancer, Gefitinib, Cancer stem cells, CD133

Background

Lung cancer is a leading cause of cancer death and predicted to be the leading cause of cancer death in 2017 in the USA [1]. In 2015, lung cancer was the leading cause of cancer deaths in men 75 years or older in China [2]. Thus, it is urgent to propose effective treatment for lung cancer. However, the lung cancer survival is hampered by its recurrence, multi-drug resistance, and metastasis [3, 4]. Lung cancer stem cells (CSCs) are considered to initiate lung cancer [5]. Some researchers hold the opinion that lung CSCs contribute to the recurrence and metastasis of lung cancer [6]. Thus, the elimination of lung CSCs could increase the therapeutic efficacy of drugs against lung cancer. The CD133 antigen is a putative CSCs marker in solid tumors including lung cancer [7–12]. CD133⁺ lung cancer cells have been shown to possess stronger potential than CD133⁻ lung cancer cells in self-renewal, proliferation, differentiation, and in vivo tumor formation in mice [11, 12].

Targeted nanoparticles with ligands such as aptamers or antibodies have attracted extensive attentions, since they could improve the targeting efficacy of chemotherapy drugs [13–15]. Although antibodies are widely applied in targeted nanoparticles, they have disadvantages such as strong immunogenicity [15]. Aptamers—oligonucleic acids—have advantages including low immunogenicity, low molecular weight, and easy production, making them ideal targeted ligands [16]. The aptamer A15 has been demonstrated to be a promising ligand for targeting CD133⁺ cells [17]. Given that CD133 is a marker of lung CSCs, we hypothesize that A15–CD133 interaction could mediate effective delivery of drugs to CD133⁺ positive lung CSCs.

Nanomicelles are nanoparticles by self-assemblies of block copolymers [18, 19]. Poly(ethylene glycol) 2000-distearoylphosphatidylethanolamine (DSPE-PEG2000) nanomicelles are promising owing to their small size and superior penetration [20–22]. We hereby constructed...
gefinitib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers (M-Gef-CD133) to target lung CSCs. Gefinitib (Iressa), a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) for treatment of non-small cell lung cancer (NSCLC) [23, 24], was used as a model drug in the study.

Methods
Reagents
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000] (DSPE-PEG2000-Mal), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamin e-N-carboxyfluorescein (CFPE) were bought from Avanti Polar Lipids (Alabaster, AL). Phycocerythrin-labeled CD133 antibodies and the CD133 MicroBead Kit were bought from Miltenyi Biotec (Auburn, CA). Gefitinib was bought from Dalian Meilun Biotech (Dalian, China). The primers and thiolated CD133 aptamers with a sequence of 5’SH-CCCCUCCUACAUAGGG-3’ were bought from Ruibo Co., Ltd. (Guangzhou, China). N-Hydroxysuccinimide (NHS), 1-ethyl-3-3-dimethylaminopropyl carbodiimide (EDC), epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF) were bought from Sigma-Aldrich (St. Louis, MO). The StemPro® Accutase® Cell Dissociation Reagent, the Reverse Transcription System kit, TRIzol® Reagent, B27, and insulin-transferrin-selenium (ITS) were bought from Thermo Fisher Scientific Inc. All organic reagents (analytical grade) were provided by Sinopharm (Shanghai, China) unless otherwise stated.

Cell culture
Human lung cancer cell lines A549 (ATCC® CCL185™, human epithelial lung cancer cells) and A431 (ATCC® CRL1555™, human epithelial epidermoid cancer cells) were provided by the American Type Culture Collection (Manassas, VA). The cells were cultured in RPMI 1640 medium with 1-glutamine supplemented with 10% FBS (fetal bovine serum) and 0.1 mM MEM non-essential amino acids in a cell incubator at 37 °C with a humidified atmosphere containing 95% air/5% CO2.

Real-time polymerase chain reaction (RT-PCR)
An RT-PCR assay was performed to examine the expression of CSC-related genes in lung cancer cells. Briefly, the first-strand complementary DNA was reverse transcribed with the Reverse Transcription System kit, after RNA was extracted with the TRIzol® Reagent. A Roche Light Cycler (Mannheim, Germany) performed the RT-PCR. The mRNA expression was expressed as 2ΔΔCt [25].

CD133 expression analyzed by flow cytometry
The collected cells were incubated with PE-CD133 antibodies (1 μg/mL) at 4 °C for 30 min, and the cells were analyzed for CD133 expression using flow cytometry (Becton Dickinson, San Jose, CA).

Magnetic cell sorting
The CD133+ cells were isolated from the lung cancer cells with magnetic cell sorting (Miltenyi Biotec.). Briefly, CD133 microbeads were added to the collected cells. Uncombined microbeads were discarded after mixing the CD133 microbeads with the cells at 4 °C for 15 min. Then, the pellet was resuspended with 500 μL PBE (PBS with 5 mM EDTA and 0.5% BSA) and separated using a magnetic separation column. After being washed, the CD133+ cells attached to the column were collected. Finally, the CD133 expression of the cells was analyzed by flow cytometry.

Tumor sphere-forming assays
Tumor sphere-forming assays are used to identify CSCs, based on their capacity to realize differentiation and self-renewal at the level of single cells [26]. Briefly, lung cancer cells (3000 cells/well) were cultured in ultra-low adherent six-well dishes (Corning, Tewksbury, MA). The cells were suspended in stem cell medium composed of DMEM/F12 (Dulbecco’s modified Eagle medium/Ham’s F-12 medium), with 1 × B27, 1 × ITS, 20 ng/mL EGF, and 20 ng/mL bFGF. The number of tumor spheres was counted after 7 days. For the formation of the second-passage tumor spheres, tumor spheres were dissociated by the StemPro® Accutase® Cell Dissociation Reagent and propagated.

Development of gefitinib-loaded nanomicelles (M-Gef)
Gefitinib-loaded nanomicelles (M-Gef) were developed with the lipid-film-based approach. In brief, 2 mg gefitinib and 10 mg DSPE-PEG2000 were dissolved in 5 mL chloroform. Then, the solvent was evaporated to form a dry lipid film. Using 5 mL phosphate-buffered saline (PBS; pH 7.4), the dried film was hydrated. With filtration through 200-nm polycarbonate membranes (Nucleopore, Whatman), free gefitinib was removed from the nanomicelles. Fluorescent nanomicelles were fabricated with the addition of 1% CFPE (mass ratio) in the lipid.

The targeted nanomicelles—gefitinib-loaded nanomicelles with CD133 aptamers (M-Gef-CD133)—were fabricated by conjugating CD133 aptamers to M-Gef by a thiol-maleimide reaction [27, 28]. In brief, M-Gef was prepared as described above, but 10 mg DSPE-PEG2000 was replaced by 10 mg lipid mixture consisting of 2 mg DSPE-PEG2000-Mal and 8 mg DSPE-PEG2000. The resultant M-Gef was incubated with CD133 aptamers...
(0.1 mg) for 6 h under stirring. After ultrafiltration with PBS, the M-Gef-CD133 was resuspended in PBS for use.

The nanomicelles were designated as follows: M-Gef-CD133 (gefitinib-loaded nanomicelles with CD133 aptamers), M-Gef (gefitinib-loaded nanomicelles), M-CD133 (blank nanomicelles conjugated with CD133 aptamers), CFPE-M-Gef-CD133 (CFPE-labeled gefitinib-loaded nanomicelles conjugated with CD133 aptamers), and CFPE-M-Gef (CFPE-labeled gefitinib-loaded nanomicelles).

The size, size distribution, zeta potential, and morphology of nanoparticles
With a Zetasizer Nano S (Malvern Instruments, UK), the size, size distribution, and zeta potential of nanomicelles were analyzed. The morphology of the nanomicelles were examined using Hitachi H-600 transmission electron microscopy (TEM, accelerating voltage of 200 kV).

The encapsulation efficiency and loading of salinomycin in nanomicelles
After being vacuum dried, 1 mL nanomicelle solution was completely dissolved in 1 mL methanol for the analysis with high-performance liquid chromatography (HPLC; L-2000, Hitachi, Japan) equipped with a reverse phase C-18 column (Diamonsil, 5 μm, 250 mm × 4.5 mm). Chromatographic conditions (mobile phase: 0.02 M dipotassium hydrogen ortho phosphate/methanol (10/90, v/v), detection wavelength: 246 nm, column temperature: 30 °C, and flow rate: 1 mL/min). The encapsulation efficacy of gefitinib = the mass of encapsulated gefitinib/the mass of total added gefitinib × 100%. The drug loading of gefitinib = the masses of encapsulated gefitinib/the mass of gefitinib-loaded nanomicelles × 100%. The CFPE concentration of nanomicelles was measured using a CFPE calibration curve.

In vitro release of gefitinib
The release of gefitinib in vitro was examined in phosphate buffer solution (PBS, pH 7.4) or PBS with 10% human plasma. Briefly, add 5 mL nanomicelle solution to the Spectra/Por® dialysis membrane (MWCO 1000). After being introduced into a vial containing release medium, the sealed tube was incubated in a water bath under gentle stirring at 37 °C (100 rpm). Two-milliliter aliquots of the dialysate were replaced with 2-mL fresh medium at different time points. The amount of gefitinib in the dialysate was measured by HPLC as described above.

Evaluation of in vitro cellular uptake of nanomicelles using flow cytometry
Lung cancer cells (5 × 10^5 cells/well) were inoculated in 12-well plates overnight. The cells were then incubated with CFPE, CFPE-M-Gef, or CFPE-M-Gef-CD133 (0.5 μg/mL equivalent CFPE concentration) for 4 h. Finally, the cells were analyzed with flow cytometry.

Evaluation of in vitro cellular uptake of gefitinib by HPLC
The intracellular uptake of gefitinib was measured by HPLC. Briefly, lung cancer cells (5 × 10^5 cells/well) were inoculated in 12-well plates overnight. Then, the cells were treated with gefitinib, M-Gef, or M-Gef-CD133 (20 μg/mL equivalent gefitinib concentration) for 4 h. The cells were then washed thrice with PBS and collected by adding 0.4 mL methanol. After the cells were sonicated for 1 min, the cell lysate was centrifuged (10,000×g for 10 min), and the supernatant was collected. HPLC quantified the gefitinib content in the supernatant. The protein concentration of supernatant was determined by the BCA™ Protein Assay Reagent Kit (Pierce). The intracellular uptake of gefitinib = gefitinib concentration/protein concentration.

Cell proliferation assays measured using CCK-8
The cytotoxic effect of the nanomicelles was examined with the CCK8 assay. Briefly, cells (1 × 10^4 cells/well) were inoculated in 96-well plates overnight. Then, the cells were treated with various concentrations of drugs (0.15~3000 μg/mL) for 48 h, and cell proliferation was examined according to the protocol of the kit.

The effect of nanomicelles on the CSC proportion of lung cancer cells
The effect of nanomicelles on the CSC proportion in lung cancer cells was examined by the tumor sphere formation and proportion of CD133^+ cells. In brief, lung cancer cells (5 × 10^4 cells/well) were inoculated in 12-well plates overnight. The cells were then treated with the nanomicelles or free gefitinib (5 μg/mL equivalent gefitinib concentration). After 24 h, the drugs were discarded, and the cells were incubated with fresh medium for 72 h. Then, the cells were trypsinized, and tumor sphere formation was performed as described above. Alternatively, the percentage of CD133^+ cells of the trypsinized cells was analyzed by flow cytometry.

In vivo tumorigenicity of lung cancer cells
Severe combined immunodeficient (SCID) mice (20 g, 6–8 weeks) provided by the Animal Breeding Center in Shanghai Institutes for Biological Sciences (Shanghai, China) were bred in specific pathogen-free (SPF) conditions. All procedures were approved by the Committee on Animal of the Second Military Medical University (Shanghai, China) and executed in accordance with guidelines of the Committee on Animal of the Second Military Medical University. The in vivo tumorigenicity assay was performed in SCID mice as described below.
Briefly, lung cancer cells (2 × 10^5) were blended with BD Matrigel™ and implanted subcutaneously into SCID mice. CD133^+ and CD133^− lung cancer cells were inoculated in both flanks of the same mice. After inoculation, the tumor formation was monitored in 50 days. Tumor volume = (width^2 × length)/2.

**Statistical analysis**

The statistic package SPSS 13.0 (SPSS Inc., Chicago, IL) was taken to analyze the data. A direct comparison between two groups was conducted with a Student’s non-paired *t* test. One-way analysis of variance (ANOVA) with the Dunnett’s or Newman–Keuls post-test compared the means of three or more groups. *P* value of < 0.05 was considered statistically significant.

**Results**

**The characteristics of nanomicelles**

The nanomicelles were fabricated by a lipid-film approach, and CD133 aptamers were conjugated to the nanomicelles by a simple thiol-maleimide reaction (Fig. 1a). As described in Table 1, all nanomicelles were rather small (~ 20 nm diameter), with a small polydispersity (PDI) (< 0.2) indicating the narrow and homogenous size distribution. The high negative zeta potential (about –20 mV) of our prepared nanomicelles predicated high stability in circulation. The EE of the nanomicelles was 8–9%, and their drug-loading efficiency was > 85%, suggesting that lipid film is effective in the encapsulation of gefitinib in nanomicelles. Thus, our prepared nanomicelles possess appropriate size, zeta potential, and drug-loading capacity.

As shown in Fig. 1c, d, both nanomicelles showed spherical shape and a disseminated pattern. M-Gef-CD133 had aggregate property which is distinct from M-Gef, which may be attributed to intermolecular forces of the aptamers conjugated to M-Gef-CD133. The in vitro release of gefitinib from M-Gef and M-Gef-CD133 was investigated (Fig. 1e, f). Both nanomicelles showed faster release in PBS with 10% plasma compared with PBS. For M-Gef and M-Gef-CD133, the drug release in PBS with 10% plasma was faster than that in PBS after 4 h (*P* < 0.05). A fast release of gefitinib (~50%) in the initial 12 h was observed. In the next 36 h, the cumulated gefitinib release of the nanomicelles was 60–70%. Taken together, both nanomicelles showed sustained drug release during 48 h.

**CD133^+ population of lung cancer cells exhibits the features of CSCs**

After magnetic cell sorting, the percentage of CD133^+ cells in lung cancer cells was > 98%. In contrast, the percentage of CD133^− cells was ~5% in the original lung cancer cell lines. CD133^+ cells were more efficient in xenograft tumor formation than CD133^− cells (Fig. 2a, b). The average tumor volume of CD133^+ cells was significantly larger compared with CD133^− cells after day 25 for A549 and day 30 for A431 (*P* < 0.05). The average tumor volume of CD133^+ A549 cells was 1340 mm^3^ on day 50, significantly larger than that of CD133^− A549 cells (567 mm^3^, *P* < 0.001) (Fig. 2a). In A431 cells, similar results were obtained (Fig. 2b). Sphere-forming assays are utilized to identify stem cells on the account of their capacity of self-renewal and differentiation at the levels of single cells [11, 12, 29]. CD133^+ A549 cells generated more tumor spheres than CD133^− A549 cells (first-passage: 77 vs. 12 for CD133^+ vs. CD133^−, *P* < 0.001; second-passage: 153 vs. 35 for CD133^+ vs. CD133^−, *P* < 0.001) (Fig. 2c). In the case of A431 cells, similar results were obtained (first-passage: 96 vs. 23 for CD133^+ vs. CD133^−, *P* < 0.001; second-passage: 163 vs. 40 for CD133^+ vs. CD133^−, *P* < 0.001).
CD133+, P < 0.001) (Fig. 2d). The CSCs genes in both CD133+ and CD133− cells was measured (Fig. 2e and f). The mRNA level of CD133 was increased by 10-fold in A549 CD133+ cells than A549 CD133− cells. The mRNA levels of OV6, OCT3/4, EpCAM, NANOG, and CD44 were also significantly higher in A549 CD133+ cells than A549 CD133− cells (P < 0.05). In the case of A431 cells, similar results were obtained. Taken together, CD133+ lung cancer cells showed the characteristics of lung CSCs.

**In vitro cellular uptake of nanoparticles**

As shown in Fig. 3a, b, in A549 CD133+ cells, the mean fluorescence intensity in the CFPE-M-Gef-CD133- treated group was significantly higher compared with CFPE-M-Gef (P < 0.05) and CFPE-treated (P < 0.05). However, we did not observe any significant difference in mean fluorescence intensity between CFPE-M-Gef-CD133 and CFPE-M-Gef-treated groups in A549 CD133− cells (P > 0.05). In the case of A431 cells, similar results were obtained (Fig. 3b). Next, we examined the quality of internalized gefitinib (Fig. 3c, d). The gefitinib concentration in the M-Gef-CD133-treated group was significantly higher compared with that in the M-Gef (P < 0.05) and gefitinib-treated groups (P < 0.05) in A549 CD133+ cells, whereas we did not observe any significant difference in gefitinib concentration between the M-Gef-CD133 and M-Gef-treated groups in A549 CD133− cells (P > 0.05). In the case of A431 cells, similar results were obtained (Fig. 3d). Taken together, these results confirm that M-Gef-CD133 showed significantly increased targeting efficacy toward CD133+ lung cancer cells compared with M-Gef.

**CCK-8 assays**

Figure 4 showed that M-CD133, blank nanomicelles with CD133 aptamers, did not induce potent cytotoxicity. In contrast, gefitinib, M-Gef, and M-Gef-CD133 showed dose-dependent cytotoxicity toward CD133+ and CD133− lung cancer cells. We used IC50 values to quantitatively measure the in vitro cytotoxicity (Table 2). The IC50 value of M-Gef-CD133 (8.5 μg/mL) was significantly lower compared with M-Gef (31.9 μg/mL) (P < 0.01) and gefitinib (78.6 μg/mL) (P < 0.001) in A549 CD133+ cells. On the contrary, the IC50 value of M-Gef-CD133 (19.8 μg/mL) did not differ significantly compared with M-Gef (21.5 μg/mL) and gefitinib (31.3 μg/mL) in A549 CD133− cells. Thus, M-Gef-CD133 was 3.8- or 9.2-fold more effective than M-Gef or gefitinib in A549 CD133+ cells, respectively. Similar results were obtained in A431 CD133+ and CD133− cells, where M-Gef-CD133 was 3.7- or 7.6-fold more effective than M-Gef or gefitinib in A431 CD133+ cells, respectively (P < 0.05). Thus, the enhanced efficacy of nanoparticles targeted toward CD133+ lung cancer cells was mainly driven by the specific binding of CD133 aptamers to CD133+ lung cancer cells.

---

**Table 1 Characteristics of nanomicelles**

| Nanomicelles | Size (nm)       | PDI    | Zeta potential (mV) | EE (%)  | Drug loading (%) |
|--------------|----------------|--------|---------------------|---------|------------------|
| M-Gef        | 21.3 ± 3.5     | 0.13 ± 0.04 | −16.8 ± 4.7         | 86.8 ± 9.2 | 9.1 ± 3.1 |
| M-Gef-CD133  | 25.8 ± 4.4     | 0.17 ± 0.06 | −18.1 ± 4.1         | 85.9 ± 3.7 | 8.3 ± 5.8 |
| M-CD133      | 20.9 ± 5.8     | 0.16 ± 0.05 | −19.2 ± 3.8         | −       | −                |

PDI: polydispersity, EE: encapsulation efficiency
Data are expressed as mean ± SD (n = 3)
cytotoxic effect of M-Gef-CD133 in CD133+ lung cancer cells could be due to their high CD133 expression.

Effect of nanomicelles on the CSC proportion in lung cancer cells
The tumor sphere formation examined the effect of nanomicelles on CSCs percentage (Fig. 5). Strikingly, in A549 cells, gefitinib and M-Gef treatment significantly increased the number of tumor spheres ($P < 0.05$), suggesting that gefitinib and M-Gef may increase the percentage of CSCs in lung cancer after treatment (Fig. 5a). Notably, relative to that in the untreated control, M-Gef-CD133 induced a twofold decrease in the number of A549 tumor spheres. The number of tumor spheres after M-Gef-CD133 treatment was smaller than gefitinib ($P < 0.001$) and M-Gef ($P < 0.001$) treatment in A549 cells. Consistently, the percentage of CD133+ A549 cells was significantly decreased after M-Gef-CD133 treatment than gefitinib ($P < 0.001$) and M-Gef ($P < 0.01$) treatment (Fig. 5c).

Similarly, relative to that in the untreated control, M-Gef-CD133 induced a 2.5-fold decrease in the number of A431 tumor spheres (Fig. 5b). The number of tumor spheres after M-Gef-CD133 treatment is smaller compared with gefitinib ($P < 0.001$) and M-Gef ($P < 0.001$), although the number of tumor spheres was significantly increased after the treatment with gefitinib and M-Gef ($P < 0.05$). Consistently, M-Gef-CD133 treatment significantly decreased the percentage of CD133+ A431 cells than gefitinib ($P < 0.001$) and M-Gef ($P < 0.01$) treatment (Fig. 5d).

Taken together, M-Gef-CD133 was demonstrated to decrease the CSC proportion in lung cancer cells, whereas gefitinib and M-Gef only increased the proportion.

Discussion
Owing to the high expression of CD133 in lung CSCs, we utilized the interaction of CD133 aptamers and CD133 as a promising approach to realize effective delivery of gefitinib to CD133-overexpressing lung CSCs. M-Gef-CD133 was developed and demonstrated to possess the potential to eliminate CD133+ lung CSCs.

Gefitinib was the first approved tyrosine kinase inhibitors (TKIs) for NSCLC [30]. However, resistance to gefitinib limits progression-free survival among patients with NSCLC [31]. The EGFR T790M secondary mutation is a well-known mechanism of gefitinib resistance [29]. Recently, studies have demonstrated that lung CSCs are involved as mutational mechanisms conferring resistance to gefitinib in NSCLC [5, 32, 33]. Consistent with those previous studies, gefitinib was demonstrated to show significantly reduced cytotoxic effects in CD133+ lung CSCs and increased the tumor...
sphere formation and proportion of CD133+ lung CSCs, suggesting that lung CSCs are resistant to gefitinib. In contrast, M-Gef-CD133 showed much higher toxicity toward CD133+ lung CSCs than toward CD133− lung cancer cells, indicating that M-Gef-CD133 overcame the gefitinib resistance. To the best of our knowledge, this is the first research that utilizes nanoparticles to overcome the gefitinib resistance of lung CSCs. As stated by Gao et al., nanoparticles represent a promising approach in eradicating CSCs by several potential mechanisms, including by improving the unfavorable pharmaceutical properties of drugs, utilizing CSC phenotype-specific ligands, and bypassing or inhibiting the efflux pump on CSCs [34].

The small size of our prepared nanomicelles (~20 nm) may be beneficial for their targeting efficacy for lung CSCs, since the size of nanoparticles is critical for their tumor penetration [35–37]. Cabral reported that the penetration ability of nanoparticles smaller than 50 nm was better than those larger than 50 nm [38]. Considering that high concentration of CSCs are often found in the central necrotic and hypoxic regions of solid tumors [39, 40], it is critical that nanoparticles possess superior penetration into solid tumors to kill CSCs. Thus, our prepared nanomicelles are expected to have superior penetration in solid tumors and kill CSCs efficiently. Owing to a technical limitation, we could not perform the penetration assay of our prepared M-Gef-CD133 in a xenograft mouse model. However, we fully realize the importance of testing the penetration of M-Gef-CD133 and will perform that assay in the future when the conditions permit.

Although gefitinib shows potent activity toward lung cancer, its solubility in water is poor [41]. Nanoparticles show promise to improve the water solubility of chemotherapy drugs [7]. One example is Abraxane® which

![Figure 4](image)

Cell proliferation assay evaluated using the CCK-8 kit. 

|                   | A549 CD133+ | A549 CD133− | A431 CD133+ | A431 CD133− |
|-------------------|-------------|-------------|-------------|-------------|
| Gefitinib         | 78.6 ± 22.5 | 31.3 ± 13.5 | 35.8 ± 17.3 | 17.9 ± 8.4  |
| M-Gef             | 31.9 ± 11.1 | 21.5 ± 13.6 | 17.6 ± 9.9  | 11.6 ± 9.5  |
| M-Gef-CD133       | 8.5 ± 5.7   | 19.8 ± 8.4  | 4.7 ± 3.2   | 13.3 ± 5.6  |
| M-CD133           | > 3000      | > 3000      | > 3000      | > 3000      |

aData are expressed as mean ± SD (n = 3). The items are defined as follows: M-Gef indicates gefitinib-loaded nanomicelles, M-Gef-CD133 indicates gefitinib-loaded nanomicelles conjugated with CD133 aptamers, and M-CD133 indicates blank nanomicelles conjugated with CD133 aptamers.
could significantly increase the drug concentrations in cancer [42]. In our study, we used nanomicelles made of DSPE-PEG2000—commercially available FDA-approved biodegradable lipid polymers—as the drug delivery system to increase gefitinib’s solubility and its targeting toward lung CSCs. Further, CD133 aptamers was pivotal in guaranteeing the targeting efficacy of M-Gef-CD133 to CD133+ lung cancer cells. First, we used flow cytometry and HPLC to demonstrate that M-Gef-CD133 could efficiently bind to CD133+ lung CSCs. Upon cell binding, M-Gef-CD133 induced enhanced cytotoxicity compared with non-targeted M-Gef and gefitinib in CD133+ lung CSCs, but not in CD133− lung cancer cells. We observed that M-Gef-CD133 reduced the number of tumor spheres and the percentage of CD133+ lung CSCs more effectively than M-Gef and gefitinib, suggesting that M-Gef-CD133 preferably eliminates CD133+ lung CSCs. In contrast, M-Gef and gefitinib increased the number of tumor spheres and the percentage of CD133+ lung CSCs. Taken together, our data have demonstrated that M-Gef-CD133 could promote the selective toxicity of gefitinib against CD133+ lung cancer cells.

There is one limitation in our study. It is needed that the lung cancer cell lines with EGFR mutations which are sensitive to gefitinib are tested in this study. However, the two available lung cancer cell lines with EGFR mutations in our lab could not form tumor spheres and thus could not be tested in this study. We completely recognize the importance of testing our nanoparticles in lung cancer cell lines with EGFR mutations and will do that in the future if possible.

**Conclusion**

This is the first study that utilizes nanoparticles to overcome the gefitinib resistance of lung CSCs. Our data demonstrated that CD133 is a promising target for the specific delivery of gefitinib to lung CSCs. M-Gef-CD133 could efficiently deliver gefitinib to CD133+ lung CSCs and induce selective toxicity against CD133+ lung CSCs. Taken together, M-Gef-CD133 represents a promising approach to target lung CSCs.

**Abbreviations**

- **DSPE-PEG2000 (ammonium salt)**: 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000];
- **DSPE-PEG2000-Mal (ammonium salt)**: 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000];
- **CFPE (ammonium salt)**: 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-carboxyfluorescein;
- **ANOVA**: Analysis of variance;
- **ATCC**: American Type Culture Collection;
- **bFGF**: Basic fibroblast growth factor;
- **CD133**: Cluster of differentiation 133;
- **cDNA**: Complementary DNA;
- **CSCs**: Cancer stem cells;
- **EDC**: 1-Ethyl-3-3-dimethylaminopropyl carbodiimide;
- **EE**: Encapsulation efficacy;
- **EGF**: Epidermal growth factor;
- **EGFR**: Epidermal growth factor receptor;
- **FBS**: Fetal bovine serum;
- **FDA**: Food and Drug Administration;
- **HPLC**: High performance liquid chromatography;
- **ITS**: Insulin-transferrin-selenium;
- **M-Gef**: Gefitinib-loaded nanomicelles;
- **M-Gef-CD133**: Gefitinib-loaded poly(ethylene glycol) 2000-distearoylphosphatidylethanolamine nanomicelles conjugated with CD133 aptamers;
- **NHS**: N-Hydroxysuccinimide;
- **NSCLC**: Non-small cell lung cancer;
- **PDI**: Polydispersity;
- **PE**: Phycoerythrin;
- **RT-PCR**: Real-time polymerase chain reaction;
- **TEM**: Transmission electron microscopy;
- **TKIs**: Tyrosine kinase inhibitors

**Acknowledgements**

Not applicable.

**Funding**

The National Natural Science Foundation of China (81300008) and Hubei Provincial Natural Science Fund (2013CFB372) supported this work.

**Availability of data and materials**

Not applicable.

**Authors’ contributions**

XH and JH designed the study. DL, SY, and QY collected the data. JS and JH performed the statistical analyses. XH and JH reviewed the results, interpreted the data, and wrote the manuscript. All authors read and approved the final version of the paper.

**Ethics approval and consent to participate**

All procedures were approved by the Committee on Animal of the Second Military Medical University (Shanghai, China) and executed in accordance with guidelines of the Committee on Animal of the Second Military Medical University.

**Consent for publication**

Not applicable.
Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. Department of Respiratory Medicine, Wuhan NO.1 Hospital, 215 Zhongshan Street, Wuhan 430022, China. 2. Laboratory Medicine, Third Hubei Provincial People’s Hospital, Zhongshan Street, Wuhan 430022, China. 3. Department of Critical Care Medicine, Wuhan NO.1 Hospital, 215 Zhongshan Street, Wuhan 430022, China. 4. Department of Otolaryngology, Wuhan NO.1 Hospital, 215 Zhongshan Street, Wuhan 430022, China. 5. Department of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, China. 6. Department of Physical examination, Wuhan Hospital for Occupational Disease Prevention and Treatment, 18-20 Jianghanbei Road, Wuhan 430016, China.

Received: 12 July 2017 Accepted: 13 August 2017
Published online: 30 August 2017

References
1. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fuji S, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2009;28:209–18.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
3. Hirsch FR, Suda K, Wiens J, Bunn PA Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388:1012–14.
4. Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016;35:75–91.
5. Jordan GT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006; 355:1253–61.
6. Hardavella G, George R, Sethi T. Lung cancer stem cells-characteristics, phenotype. Transl Lung Cancer Res. 2016;5:272–9.
7. Gao J, Li W, Guo Y. Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells. Nanomedicine (Lond). 2016;11:3261–82.
8. Xie F, Xu W, Yin C, Zhang G, Zhong Y, Gao J. Nanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive system. World J Gastrointest Oncol. 2016;8:735–44.
9. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jameson CH, Jones DS, Visvader J, Weissman IL, Wahl GM. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:3939–44.
10. Lundin A, Drouillard B. Lung cancer stem cells: progress and prospects. Cancer Lett. 2013;338:89–93.
11. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Lombardi M, Viale G, et al. Lung cancer stem cells: characteristics, phenotype, tumor aggressiveness, and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2010;70:4939–44.
12. Eramo A, Sette G, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic CD133+ lung cancer stem cell population. Cell Death Differ. 2008;15(3):504–12.
13. Manjappa AS, Chaudhari KR, Venkataramu MP, Dantuluri P, Nana B, Sidda C, Sawant RK, Murthy RS. Antibody derativation and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumors. J Control Release. 2011;150:2–11.
14. Choi HS, Liu W, Liu F, Nasr K, Misra P, Bawendi MG, Frangioni JV. Design considerations for tumor-targeted nanoparticles. Nat Nanotechnol. 2010;5:42–7.
15. Gao J, Feng SS, Guo Y. Antibody engineering promotes nanomedicines for cancer treatment. Nanomedicine (Lond). 2010;5:1141–5.
16. Klee AE, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9:57–50.
17. Shigdar S, Qiao L, Zhou SF, Xiang D, Wang T, Li Y, Lim LY, Kong L, Li L, Duan W. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett. 2013;330:84–95.
40. Grainger SJ, Serna JV, Sunny S, Zhou Y, Deng CX, El-Sayed ME. Pulsed ultrasound enhances nanoparticle penetration into breast cancerspheroids. Mol Pharm. 2010;7:2006–19.

41. Shi Y, Su C, Cui W, Li H, Liu L, Feng B, Liu M, Su R, Zhao L. Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells. J Nanobiotechnol. 2014;12:43.

42. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, Hawkins MJ. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17:1263–8.